

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

(Securities Code: 4974)

June 3, 2021

To our shareholders:

Koichi Nakao, President

Takara Bio Inc.

7-4-38, Nojihigashi, Kusatsu-shi, Shiga

Notice of the 19th Annual General Meeting of Shareholders

We are pleased to announce the 19th Annual General Meeting of Shareholders of Takara Bio Inc. (the “Company”), which will be held as indicated below.

In view of the situation regarding the novel coronavirus disease (COVID-19), from the perspective of preventing the spread of infection, we request all shareholders to exercise their voting rights in advance in writing or via the internet, etc. and to refrain from attending the meeting in person regardless of their health condition.

Please review the attached Reference Documents for General Meeting of Shareholders and exercise your voting rights by Wednesday, June 23, 2021, at 5:30 p.m. (JST).

[Voting via the Internet]

Please review the “Instructions on Exercise of Voting Rights via the Internet” (in Japanese only), access to the voting website designated by the Company, and enter your approval or disapproval of the proposals according to on-screen instructions by the deadline indicated above.

[Voting by Mail]

Please indicate your approval or disapproval of the proposals in the enclosed voting form and return it so that your vote is received by the voting deadline indicated above.

1. Date and Time: Thursday, June 24, 2021, at 10:00 a.m. (JST)

2. Venue: Prince Hall, 3F, Lake Biwa Otsu Prince Hotel
4-7-7, Nionohama, Otsu-shi, Shiga

Please note that, as a measure to prevent the spread of COVID-19, shareholders will be seated at a distance from each other, and therefore there will be significantly fewer seats available compared to the past years. In light of this, please be aware that even shareholders who come to the venue may not be allowed to enter. We appreciate your understanding.

3. Purpose of the Meeting

Matters to be reported:

1. The Business Report and the Consolidated Financial Statements for the 19th fiscal year (from April 1, 2020 to March 31, 2021), and the results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit & Supervisory Board
2. The Non-consolidated Financial Statements for the 19th fiscal year (from April 1, 2020 to March 31, 2021)

Matters to be resolved:

- | | |
|-----------------------|--|
| Proposal No. 1 | Appropriation of Surplus |
| Proposal No. 2 | Election of Nine Directors |
| Proposal No. 3 | Election of One Audit & Supervisory Board Member |

- There is concern about the risk of infection with the novel coronavirus. Shareholders who intend to attend this general meeting of shareholders in person are kindly requested to pay close attention to their physical condition until the day of the meeting and take care to ensure that they do not overextend themselves.
- We ask that elderly shareholders or those with underlying medical conditions, who are considered to be highly susceptible to infection, or those who are not in good health would make a careful decision to avoid the risk of infection as a matter of priority.
- At the venue of this General Meeting of Shareholders, we will take measures to prevent infection of COVID-19, such as wearing a mask and disinfecting with alcohol. We would appreciate it if you could cooperate with us in this regard.
- In order to avoid risk of infection, there will be no gifts provided at the meeting this year. We appreciate your understanding.
- We will make no area to introduce our business activities, which is held every year in order to gain a deeper understanding of the Company, from the viewpoint of avoiding the risk of the infection.
- There will also be no drinks provided at the meeting this year.
- If you attend the meeting in person, please present the enclosed voting form at the venue's reception. The reception desk is scheduled to open at 9:00 a.m.
- Please note that anyone other than a shareholder who is entitled to exercise voting rights (e.g., non-shareholding proxy, person accompanying the shareholder) will not be allowed inside the venue.
- Of the documents that should be attached to the notice, the following documents are posted on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>), pursuant to laws and regulations and the provisions in Article 14 of the Company's Articles of Incorporation, and are not attached to the notice.
 1. Business Report:
Overview of Systems to Ensure Properness of Operations and Outline of Management of Such Systems
 2. Consolidated Financial Statements:
Consolidated Statement of Changes in Equity and Notes to the Consolidated Financial Statements
 3. Non-consolidated Financial Statements:
Statement of Changes in Equity and Notes to the Non-consolidated Financial Statements

Consequently, the documents attached to the notice are part of the Consolidated Financial Statements and the Non-consolidated Financial Statements that were audited by the Accounting Auditor in preparing the financial audit report and part of the Business Report, the Consolidated Financial Statements and the Non-consolidated Financial Statements that were audited by the Audit & Supervisory Board Members in preparing the audit report.
- If any revision is made to the Reference Documents for General Meeting of Shareholders, the Business Report, the Consolidated Financial Statements and the Non-consolidated Financial Statements, the Company will post such revision on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>).
- The Company participates in "electronic voting platforms" for institutional investors operated by ICJ Inc.
- To ensure that information is furnished in a timely manner, the content of this Notice was disclosed on the Company's website (<https://ir.takara-bio.co.jp/ja/stock/meeting.html>) before it was sent out.
- If there are any major changes in the way the General Meeting of Shareholders is held due to future developments regarding infections with the novel coronavirus, we will post an announcement on the Company's website (<https://www.takara-bio.co.jp>).

Proposal No. 2 Election of Nine Directors

At the conclusion of this meeting, the terms of office of all nine Directors will expire. In that regard, the Company proposes the election of nine Directors (three of whom are external Directors). The candidates for Director are as follows:

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
1	<p>Hisashi Omiya June 9, 1943</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company Please refer to the details below. Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1968 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>May 1974 Director</p> <p>June 1982 Managing Director</p> <p>June 1988 Senior Managing Director</p> <p>June 1991 Representative Director and Vice President</p> <p>June 1993 Representative Director and President</p> <p>Apr. 2002 Chairman of the Company (current position)</p> <p>Apr. 2002 Representative Director and President of Takara Shuzo Co., Ltd.</p> <p>June 2012 Representative Director and Chairman of Takara Holdings Inc. (current position) Representative Director and Chairman of Takara Shuzo Co., Ltd. (current position)</p> <p>July 2017 Representative Director and Chairman of Takara Shuzo International Co., Ltd. (current position)</p> <p>Significant concurrent positions outside the Company Representative Director and Chairman of Takara Holdings Inc. Representative Director and Chairman of Takara Shuzo Co., Ltd. Representative Director and Chairman of Takara Shuzo International Co., Ltd.</p>	220,700 shares
<p>Reasons for nomination as candidate for Director, etc.</p> <p>- Mr. Omiya is the founder of the bio business in the Takara Holdings Group and is familiar with the biotechnology industry. He possesses abundant experience and knowledge gained as an officer of the Takara Holdings Group over many years, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p>- Mr. Omiya is currently a business executive (Representative Director and Chairman) of the Company's parent company Takara Holdings Inc. and its subsidiaries (so-called fellow subsidiaries of the Company) Takara Shuzo Co., Ltd. and Takara Shuzo International Co., Ltd., and has also been a business executive (Representative Director and Chairman, Representative Director and President) of each of the above companies for the past ten years.</p> <p>Relationship of special interest in the Company The Company has the following transactions with Takara Holdings Inc. and Takara Shuzo Co., Ltd., where Mr. Omiya serves as Representative Director and Chairman.</p> <p>(i) With Takara Holdings Inc., the Company has transactions including the Company's payment of license fees for use of trademarks, payment for outsourcing of computer-related services and lease of information equipment, and transactions concerning office leases.</p> <p>(ii) With Takara Shuzo Co., Ltd., the Company has transactions including the Company's payment of office rent, payment for purchased products, and other transactions concerning product sales and contracted services.</p> <p>Directors and officers liability insurance policy The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
2	<p data-bbox="363 562 507 622">Koichi Nakao June 16, 1962</p> <p data-bbox="376 658 494 687">[Reelection]</p> <p data-bbox="284 723 587 784">Relationship of special interest in the Company None</p> <p data-bbox="323 819 547 909">Attendance at Board of Directors meetings 12/12 (100%)</p>	<p data-bbox="611 264 1238 324">Apr. 1985 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p data-bbox="611 331 1015 360">Apr. 2002 Director of the Company</p> <p data-bbox="611 367 1177 396">June 2003 Managing Director and Executive Officer</p> <p data-bbox="611 403 1169 463">June 2004 Senior Managing Director and Executive Officer</p> <p data-bbox="611 470 1214 530">Apr. 2006 Senior Managing Director, Executive Officer, and COO</p> <p data-bbox="611 537 1161 598">June 2007 Representative Director, Vice President, Executive Officer, and COO</p> <p data-bbox="611 604 1201 665">June 2008 Representative Director, Vice President, and COO</p> <p data-bbox="611 672 1225 732">May 2009 Representative Director and President (current position)</p> <p data-bbox="611 739 1238 799">June 2009 Representative Director and President of Takara Bio USA Holdings Inc. (current position)</p> <p data-bbox="611 806 1174 866">June 2009 Director of Takara Holdings Inc. (current position)</p> <p data-bbox="611 873 1145 934">June 2015 President and Executive Officer of the Company (current position)</p> <p data-bbox="611 940 1214 1023">Apr. 2021 Representative Director of Manufacturing Technology Association of Biologics (current position)</p> <p data-bbox="611 1030 1174 1120">Significant concurrent positions outside the Company Representative Director and President of Takara Bio USA Holdings Inc. Director of Takara Holdings Inc. Representative Director of Manufacturing Technology Association of Biologics</p>	69,500 shares
<p data-bbox="272 1214 799 1243">Reasons for nomination as candidate for Director, etc.</p> <p data-bbox="272 1249 1430 1339">- Mr. Nakao has displayed leadership as Representative Director of the Company and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p data-bbox="272 1346 1437 1435">- Mr. Nakao is currently a business executive (Representative Director and President) of Takara Bio USA Holdings Inc., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company, and has also been a business executive (Representative Director and President) of the company for the past ten years.</p> <p data-bbox="272 1442 1430 1532">- Within the past ten years, Mr. Nakao has served as a business executive (Chairman) of Takara Biotechnology (Dalian) Co., Ltd., Takara Biomedical Technology (Beijing) Co., Ltd., and Takara Korea Biomedical Inc., which are subsidiaries of the Company's parent company Takara Holdings Inc. as well as subsidiaries of the Company.</p> <p data-bbox="272 1538 735 1568">Directors and officers liability insurance policy</p> <p data-bbox="272 1574 1437 1720">The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
3	<p data-bbox="355 434 520 495">Junichi Mineno August 13, 1960</p> <p data-bbox="376 528 499 562">[Reelection]</p> <p data-bbox="284 595 592 656">Relationship of special interest in the Company None</p> <p data-bbox="323 689 552 786">Attendance at Board of Directors meetings 12/12 (100%)</p>	<p data-bbox="611 264 1238 324">Apr. 1984 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p data-bbox="611 336 1217 396">Apr. 2004 General Manager of Center for Cell and Gene Therapy Facility of the Company</p> <p data-bbox="611 407 1222 490">June 2009 Deputy General Manager of Gene Therapy Business Unit and General Manager of Center for Cell and Gene Therapy Facility</p> <p data-bbox="611 501 948 535">Apr. 2011 Executive Officer</p> <p data-bbox="611 546 1015 580">June 2012 Senior Executive Officer</p> <p data-bbox="611 591 959 624">June 2014 Managing Director</p> <p data-bbox="611 636 1171 696">June 2015 Managing Director and Senior Executive Officer</p> <p data-bbox="611 707 1238 768">July 2016 Representative Director and Vice Chairman of Takara Korea Biomedical Inc. (current position)</p> <p data-bbox="611 779 1171 840">June 2019 Director and Senior Managing Executive Officer (current position)</p> <p data-bbox="611 851 986 884">Current responsibility in the Company COO (Chief Operating Officer)</p> <p data-bbox="611 896 1134 929">Significant concurrent positions outside the Company Representative Director and Vice Chairman of Takara Korea Biomedical Inc.</p>	14,400 shares
<p data-bbox="276 958 799 992">Reasons for nomination as candidate for Director, etc.</p> <p data-bbox="276 992 1425 1144">- Mr. Mineno has engaged in R&D of new technologies and new projects, genetic analysis-related business and businesses related to products and services for clinical research on cell and gene therapies. He possesses a track record of establishing its GMP production framework in the gene therapy business, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p data-bbox="276 1144 1425 1272">- Mr. Mineno is currently a business executive (Representative Director and Vice Chairman) of Takara Korea Biomedical Inc., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company, and has also been a business executive (Representative Director and Vice Chairman) of the company for the past ten years.</p> <p data-bbox="276 1272 735 1305">Directors and officers liability insurance policy</p> <p data-bbox="276 1305 1445 1462">The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
4	<p>Masanobu Kimura August 19, 1963</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>July 2001 Joined Daiichi Pharmaceutical Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)</p> <p>Mar. 2007 Joined ImmunoFrontier, Inc.</p> <p>Mar. 2010 Joined ICON Japan K.K.</p> <p>Nov. 2011 Joined PAREXEL International Inc.</p> <p>May 2013 Joined the Company</p> <p>Apr. 2015 Deputy General Manager of Gene Therapy Business Unit and General Manager of Project Management Department</p> <p>June 2016 Executive Officer</p> <p>June 2017 Director and Managing Executive Officer (current position)</p> <p>Current responsibility in the Company General Manager of Clinical Development Division</p>	800 shares
<p>Reasons for nomination as candidate for Director Mr. Kimura has been involved in development of pharmaceuticals, has leadership experience in clinical development in the gene therapy business, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as a Director.</p> <p>Directors and officers liability insurance policy The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
	<p>Tsuyoshi Miyamura October 20, 1963</p> <p>[Reelection]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p>	<p>Apr. 1988 Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.)</p> <p>Jan. 2009 General Manager of Sales Department of the Company</p> <p>June 2009 Executive Officer</p> <p>June 2014 Managing Executive Officer (current position)</p> <p>June 2018 Director (current position)</p> <p>Dec. 2019 Chairman of Takara Biomedical Technology (Beijing) Co., Ltd. (current position)</p> <p>Mar. 2021 Representative Director and Chairman of Takara Korea Biomedical Inc. (current position)</p> <p>Current responsibility in the Company CMO (Chief Marketing Officer)</p> <p>Significant concurrent positions outside the Company Chairman of Takara Biomedical Technology (Beijing) Co., Ltd. Representative Director and Chairman of Takara Korea Biomedical Inc.</p>	<p>9,700 shares</p>
5	<p>Reasons for nomination as candidate for Director, etc.</p> <ul style="list-style-type: none"> - Mr. Miyamura has been involved in planning, marketing, sales and distribution of products and services in the bio business, has contributed to the market expansion in China for products in the genetic engineering research field, proved his ability as a corporate manager for the Company's subsidiary, and meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate to continue serving as Director. - Mr. Miyamura is currently a business executive of Takara Biomedical Technology (Beijing) Co., Ltd. (as Chairman), and of Takara Korea Biomedical Inc. (as Representative Director and Chairman), which are both subsidiaries of the Company's parent company Takara Holdings Inc. as well as subsidiaries of the Company, and has also been a business executive (Chairman, and Representative Director and Chairman, respectively) of both of the companies for the past ten years. - Within the past ten years, Mr. Miyamura has served as a business executive (Chairman) of Takara Biotechnology (Dalian) Co., Ltd., which is a subsidiary of the Company's parent company Takara Holdings Inc. as well as a subsidiary of the Company. <p>Directors and officers liability insurance policy</p> <p>The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>		

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
6	<p data-bbox="357 338 517 394">Yoh Hamaoka October 9, 1962</p> <p data-bbox="357 434 517 461">[New election]</p> <p data-bbox="284 501 593 557">Relationship of special interest in the Company None</p> <p data-bbox="325 598 552 654">Attendance at Board of Directors meetings -</p>	<p data-bbox="612 264 715 291">Apr. 1987</p> <p data-bbox="612 300 715 327">Feb. 2000</p> <p data-bbox="612 367 715 394">Apr. 2004</p> <p data-bbox="612 403 715 430">June 2009</p> <p data-bbox="612 501 715 528">Apr. 2017</p> <p data-bbox="612 600 715 627">June 2018</p> <p data-bbox="612 636 715 663">Apr. 2019</p> <p data-bbox="612 672 715 698">Apr. 2020</p> <p data-bbox="612 707 986 757">Current responsibility in the Company CFO (Chief Financial Officer)</p> <p data-bbox="772 264 1241 757"> Joined Japan Tobacco Inc. Joined Takara Shuzo Co., Ltd. (currently Takara Holdings Inc.) Executive Officer of the Company Senior Executive Officer (current position) and Deputy General Manager of Gene Therapy Business Unit In charge of Intellectual Property Department and General Manager of Business Development Department In charge of General Affairs Department In charge of Project Management Department General Manager of R&D Division </p>	16,800 shares
<p data-bbox="276 763 756 790">Reasons for nomination as candidate for Director</p> <p data-bbox="276 799 1423 920">- Mr. Hamaoka has been involved in business development, intellectual property, project promotion and planning, public relations and investor relations, general affairs, and finance, and is well-versed in the Company's operations in the corporate sector, and also meets the criteria for candidates for Director established by the Company. Therefore, the Company nominated him as a candidate for Director.</p> <p data-bbox="276 929 735 956">Directors and officers liability insurance policy</p> <p data-bbox="276 965 1449 1106">The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his appointment is approved, he will be included as an insured under the policy.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
	<p>Nobuko Kawashima October 27, 1962 (Name as shown on the family register: Nobuko Yokoyama)</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p> <p>Number of years in office as an external Director 5 years (at the conclusion of this meeting)</p>	<p>Apr. 1986 Joined The Long-Term Credit Bank of Japan, Limited (currently Shinsei Bank, Limited)</p> <p>Sept. 1987 Joined Dentsu Communication Institute Inc.</p> <p>Sept. 1995 Research fellow at the Centre for Cultural Policy Studies of the University of Warwick</p> <p>Apr. 1999 Full-time lecturer with the Faculty of Economics at Doshisha University</p> <p>Apr. 2004 Professor with the Faculty of Economics (current position)</p> <p>June 2016 Director (external Director) of the Company (current position)</p> <p>June 2021 Director (Outside Director) of TOKAI Holdings Corporation (scheduled to assume the position)</p> <p>Significant concurrent positions outside the Company Professor with the Faculty of Economics at Doshisha University Director (Outside Director) of TOKAI Holdings Corporation [scheduled to assume the position in June 2021]</p>	<p>0 shares</p>
7	<p>Reasons for nomination as candidate for external Director and outline of expected roles, etc.</p> <ul style="list-style-type: none"> - Ms. Kawashima is a candidate for external Director. - Ms. Kawashima has extensive research experience in subjects including creative economy and corporate social responsibility. She meets the criteria for candidates for external Director established by the Company, and is expected to apply her expert knowledge to the management of the Company and express her opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated her as a candidate to continue serving as an external Director. - Ms. Kawashima has never in the past been involved in the management of a company except as an external officer. However, the Company judges she will appropriately fulfill her duties as an external Director based on her abundant experience as an academic and broad insight on economy and society. - Ms. Kawashima satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning her appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Ms. Kawashima to limit her liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Ms. Kawashima is approved, the Company plans to renew the aforementioned agreements with her.</p> <p>Directors and officers liability insurance policy</p> <p>The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If her reappointment is approved, she will be included as an insured under the policy.</p>		

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
8	<p data-bbox="357 546 517 607">Kazuko Kimura May 1, 1951</p> <p data-bbox="325 645 549 674">[Reelection - External]</p> <p data-bbox="284 707 590 768">Relationship of special interest in the Company None</p> <p data-bbox="325 801 549 893">Attendance at Board of Directors meetings 12/12 (100%)</p> <p data-bbox="284 904 590 1021">Number of years in office as an external Director 2 years (at the conclusion of this meeting)</p>	<p data-bbox="612 264 1241 356">Apr. 1976 Safety and Environmental Health Bureau, Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare)</p> <p data-bbox="612 367 1082 396">Apr. 1979 Pharmaceutical Affairs Bureau</p> <p data-bbox="612 407 1219 468">July 1996 Pharmaceutical Department of World Health Organization (on secondment)</p> <p data-bbox="612 479 1209 517">July 1999 Organization for Pharmaceutical Safety and Research (on secondment)</p> <p data-bbox="612 528 1214 651">Apr. 2000 Professor of International Medical Research Laboratory, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University</p> <p data-bbox="612 663 1150 723">June 2013 Director (Outside Director) of Alfresa Holdings Corporation</p> <p data-bbox="612 734 1235 795">Sept. 2013 Representative Director of Medicines Security Workshop (current position)</p> <p data-bbox="612 806 1198 889">Apr. 2017 Professor Emeritus of National University Corporation Kanazawa University (current position)</p> <p data-bbox="612 900 1230 960">Oct. 2017 Specially Appointed Professor of Graduate School of Medical Sciences (current position)</p> <p data-bbox="612 972 1214 1032">June 2019 Director (external Director) of the Company (current position)</p> <p data-bbox="612 1043 1209 1104">June 2021 Director (Outside Director) of Mitsubishi Logistics Corporation (scheduled to assume the position)</p> <p data-bbox="612 1126 1241 1301">Significant concurrent positions outside the Company Specially Appointed Professor of Graduate School of Medical Sciences, National University Corporation Kanazawa University Representative Director of Medicines Security Workshop Director (Outside Director) of Mitsubishi Logistics Corporation [scheduled to assume the position in June 2021]</p>	0 shares

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
		<p>Reasons for nomination as candidate for external Director and outline of expected roles, etc.</p> <ul style="list-style-type: none"> - Ms. Kimura is a candidate for external Director. - Ms. Kimura is a specialist in the areas of quality control of pharmaceutical distribution, eradication of substandard and falsified medicines, support of development of anti-counterfeit technologies, and education of specialists. She meets the criteria for candidates for external Director established by the Company, and is expected to apply her expert knowledge to the management of the Company and express her opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated her as a candidate to continue serving as an external Director. - Ms. Kimura has never in the past been involved in the management of a company except as an external officer. However, the Company judges she will appropriately fulfill her duties as an external Director based on her abundant experience as an academic and broad insight on quality control of pharmaceutical distribution, etc. - Ms. Kimura satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning her appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Ms. Kimura to limit her liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Ms. Kimura is approved, the Company plans to renew the aforementioned agreements with her.</p> <p>Directors and officers liability insurance policy</p> <p>The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If her reappointment is approved, she will be included as an insured under the policy.</p>	

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
9	<p>Noriomi Matsumura July 10, 1971</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 10/10 (100%) (After assuming office on June 23, 2020)</p> <p>Number of years in office as an external Director 1 year (at the conclusion of this meeting)</p>	<p>May 1998 Medical Staff with Department of Obstetrics and Gynecology at Hyogo Prefectural Amagasaki Hospital</p> <p>Apr. 2000 Medical Staff with Department of Obstetrics and Gynecology at Toyooka Public Hospital</p> <p>Sept. 2002 Medical Staff with Department of Obstetrics and Gynecology at Kyoto University Hospital</p> <p>Apr. 2007 Clinical Assistant Professor with Department of Obstetrics and Gynecology at National University Corporation Kyoto University Hospital</p> <p>Apr. 2008 Assistant Professor with Department of Gynecology and Obstetrics</p> <p>Dec. 2012 Lecturer with Maternal and Perinatal Care Unit</p> <p>Aug. 2013 Associate Professor with Department of Gynecology and Obstetrics</p> <p>Apr. 2017 Professor with Department of Obstetrics and Gynecology of Faculty of Medicine at Kindai University (current position)</p> <p>June 2017 Vice Chairperson of Board Certification Committee of Japan Society of Obstetrics and Gynecology (current position)</p> <p>Dec. 2018 Director and TR Committee Member, Japanese Gynecologic Oncology Group (current position)</p> <p>June 2020 Director (external Director) of the Company (current position)</p> <p>July 2020 Board Member of Japan Society of Gynecologic Oncology (current position)</p> <p>Significant concurrent positions outside the Company Professor with Department of Obstetrics and Gynecology of Faculty of Medicine at Kindai University</p>	0 shares

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
		<p>Reasons for nomination as candidate for external Director and outline of expected roles, etc.</p> <ul style="list-style-type: none"> - Mr. Matsumura is a candidate for external Director. - Mr. Matsumura possesses abundant experience and expert knowledge in obstetrics and gynecology and other fields of medical science in general, and is familiar particularly with the areas of tumor genome analysis, molecular targeted therapy, and immune therapy of gynecologic oncology. He meets the criteria for candidates for external Director established by the Company, and is expected to utilize his experience and expertise and express his opinions at the Board of Directors meetings from an independent and objective standpoint, thereby ensuring effective management oversight. Therefore, the Company nominated him as a candidate to continue serving as an external Director. - Mr. Matsumura has never in the past been involved in the management of a company except as an external officer. However, the Company judges he will appropriately fulfill his duties as an external Director based on his abundant experience as an academic and broad insight on medical science in general. - Mr. Matsumura satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning his appointment as an independent officer. <p>Limited liability agreement</p> <p>Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Mr. Matsumura to limit his liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Mr. Matsumura is approved, the Company plans to renew the aforementioned agreements with him.</p> <p>Directors and officers liability insurance policy</p> <p>The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.</p>	

Proposal No. 3 Election of One Audit & Supervisory Board Member

The term of office of Audit & Supervisory Board Member Masaaki Makikawa will expire at the conclusion of this meeting.

Therefore, the Company proposes the election of one Audit & Supervisory Board Member (external Audit & Supervisory Board Member).

In addition, the consent of the Audit & Supervisory Board has been obtained for this proposal.

The candidate for Audit & Supervisory Board Member is as follows:

Name (Date of birth)	Career summary and position in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
<p>Masaaki Makikawa January 1, 1952</p> <p>[Reelection - External]</p> <p>Relationship of special interest in the Company None</p> <p>Attendance at Board of Directors meetings 12/12 (100%)</p> <p>Attendance at Audit & Supervisory Board meetings 13/13 (100%)</p> <p>Number of years in office as an Audit & Supervisory Board Member 4 years (at the conclusion of this meeting)</p>	<p>Apr. 1996 Professor with the Department of Robotics of the Faculty of Science and Engineering at Ritsumeikan University</p> <p>Apr. 2003 Head of the Liaison Office of Biwako-Kusatsu Campus</p> <p>Apr. 2005 Head of the Research Center for Sport and Health Science</p> <p>Apr. 2007 Executive Director of the Institute of Science and Technology</p> <p>Apr. 2011 Visiting Professor with the Graduate School of Medicine at Osaka University (current position)</p> <p>Apr. 2012 Dean of the Research Division at Ritsumeikan University</p> <p>Apr. 2017 Specially Appointed Professor with the Faculty of Science and Engineering</p> <p>June 2017 Audit & Supervisory Board Member (External Audit & Supervisory Board Member) of the Company (current position)</p> <p>July 2017 Special Professor with the Faculty of Science and Engineering (Assistant Director) (current position)</p> <p>Apr. 2021 President of Osaka Hatsushiba Trust(current position)</p> <p>Significant concurrent positions outside the Company Special Professor with the Faculty of Science and Engineering (Assistant Director) at Ritsumeikan University President of Osaka Hatsushiba Trust</p>	<p>0 shares</p>

Reasons for nomination as candidate for external Audit & Supervisory Board Member, etc.

- Mr. Makikawa is a candidate for external Audit & Supervisory Board Member.

- Mr. Makikawa possesses experience and expertise in industry academia collaboration projects, such as research management of national projects and many commissioned research and joint research, in the fields of medical engineering and bioengineering. He meets the criteria for candidates for external Audit & Supervisory Board Member established by the Company, and, in this role, is expected to reflect such experience and expertise in audits of the Company. Therefore, the Company nominated him as a candidate to continue serving as an external Audit & Supervisory Board Member.

- Mr. Makikawa has never in the past been involved in the management of a company except as an external officer. However, the Company judges that he will appropriately fulfill his duties as an external Audit & Supervisory Board Member based on the above reasons.

- Mr. Makikawa satisfies the requirements for an independent officer as provided for by Tokyo Stock Exchange, Inc., and the Company has submitted notification to the aforementioned exchange concerning his appointment as an independent officer.

Limited liability agreement

Pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company has entered into an agreement with Mr. Makikawa to limit his liability for damages under Article 423, paragraph 1 of the Companies Act. Pursuant to this agreement, the defined maximum amount of liability for damages is the minimum liability amount provided for under Article 425, paragraph 1 of the same Act. If the reelection of Mr. Makikawa is approved, the Company plans to renew the aforementioned agreements with him.

Directors and officers liability insurance policy

The Company has entered into a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph 1 of the Companies Act, which covers damages and litigation expenses incurred by the insured due to claims for damages arising from the insured's actions as a director or officer. In addition, when the policy is renewed, the Company plans to renew the policy with the same terms. If his reappointment is approved, he will be included as an insured under the policy.